Good MorningEquity markets rebounded on Monday as investors hoped for FOMC leniency. The budding banking crisis is the first sign of economic cracking and, for some, a reason the FOMC should quit hiking rates. The caveat is that inflation is still high, and the latest data supports the Fed's current policy stance. However, the FOMC may only raise by 25 basis points but issue a firm statement that says the committee will act when the data is hot.
A new round of aid for trouble bank First Republic helped soothe fears of contagion. A consortium of banks led by JPMorgan Chase & Co. is seeking ways to raise capital for the bank and shore up its balance sheet. Among the possibilities are dilutive share sales and an outright bank sale. Meanwhile, the banking fallout has investors in the EU on edge, which is another sign that global economic conditions are on the brink of collapse. Featured: F1 Engineering Powers This Electric Marine Motor (Ad) 
|
Tech | | | After sweeping through battles in statehouses across the country, the war against ESG investing is heating up in Congress.
The Senate voted Wednesday to overturn a Labor Department rule allowing retirement plans to consider environmental, social and governance factors when making inve... Read the Full Story |
|
From Our Partners | | 5 Stocks That Could Double in 2025 🚀
Our analysts have identified five stocks with the potential to double in 2025. From a company poised to lead the crypto ETF market to an innovator in fuel cell technology for AI and data centers, these picks could be game-changers for your portfolio. | | Don’t miss these insights. |
|
Stocks | | |
It’s no secret to many investors that some of the largest gains come from investing in small-cap stocks. These stocks can get overlooked because of their market capitalization. But that would be a mistake. Historical patterns show that frequently small-cap stocks are the ones that perform th... Read the Full Story |
|
Markets | | | Credit Suisse shares plunged Monday after Swiss authorities cut a deal with its bigger rival UBS to acquire the troubled bank at a marked-down price. But European bank stocks and the wider market gained as investors watch whether moves to shore up banks will stem further upheaval in the global finan... Read the Full Story |
|
From Our Partners | | We’ve got seven great summertime plays for you. These stocks are in a prime position to reward your portfolio… especially if you take action before summer is in full swing!
They cover summer-centric industries such as solar, home improvement, entertainment, travel, and more.
To keep you motivated during these summer months, we’d like to give you a FREE report revealing these companies – 7 Best Stocks to Own in Summer 2025. | | Get Your Copy of "7 Best Stocks to Own in Summer 2025" Here. |
|
Stocks | | |
First, it was Silicon Valley Bank. Then Signature Bank. First Republic Bank is assumed to be the next domino to fall in the evolving U.S. banking crisis.
Whether higher interest rates or company mismanagement are to blame, one thing is clear — people are concerned. Worried about the s... Read the Full Story |
|
Markets | | | In a bid to ease turmoil in the world financial system, Swiss authorities engineered a plan for the UBS bank to acquire its troubled smaller rival Credit Suisse at a marked-down price.It's another urgent attempt to fight fears that have put the financial world on edge 15 years after the failure of U... Read the Full Story |
|
From Our Partners | | Something extraordinary is happening in Washington.
For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations.
I'm talking about a $150 trillion American asset that's scattered across all 50 states.
While the mainstream media focuses on political theater, this story is quietly developing behind closed doors. | | We recently interviewed Rickards to get the full story and understand how everyday Americans can pre |
|
Markets | | | Look no further if you want yield and distribution growth in a large-cap name with a blue-chip appeal. A simple screen using Marketbeat.com’s dividend screener will turn up names like Comcast (NASDAQ: CMCSA), Bristol-Myers Squibb (NYSE: BMY), and Amgen (NYSE: AMGN), among others. These co... Read the Full Story |
|
Stocks | | |
The entire chip sector shows a bottom and is on the cusp of reversal, with NVIDIA (NASDAQ: NVDA) in the lead. The company’s Q4 results were better than expected due to unexpected strengths that led to solid guidance. The stock is up about 150% from its latest bottom and on track to hit... Read the Full Story |
|
Markets | | |
Build-A-Bear Workshop Inc. (NYSE: BBW) started as a niche retailer in shopping malls selling plush dolls that children could bring to life in the store by adding stuffing, a heart with a recordable message, along with other customizable options. The customer can name the doll, buy clothing and acc... Read the Full Story |
|
Markets | | | While Wall Street works to contain the biggest American bank failure since the 2008 financial meltdown, founders of startups who are people of color worry it could become even harder to secure financial support Read the Full Story |
|
Stocks | | | Two large banks that cater to the tech industry have collapsed after a bank run, government agencies are taking emergency measures to backstop the financial system, and President Joe Biden is reassuring Americans that the money they have in banks is safe Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. | | View Today's Stock Pick |
|
